Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (2)
  • Apoptosis
    (1)
  • Bcl-2 Family
    (1)
  • HIV Protease
    (1)
  • Others
    (6)
Filter
Search Result
Results for "

cdk-9-in-1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    9
    TargetMol | Inhibitors_Agonists
CDK9-IN-1
T107411415559-43-1
CDK9-IN-1 is a selective and potent CDK9 inhibitor with antiviral activity used in the study of PRRSV infections.
  • Inquiry Price
7-10 days
Size
QTY
A09-003
T794042911646-14-3In house
A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.A09-003 also induces apoptosis, decreases RNA polymerase II activity, and decreases Mcl-1 expression.
  • Inquiry Price
6-8 weeks
Size
QTY
CKD-712
CKD 712,CKD712
T27033626252-75-3
CKD-712 is a nuclear factor NF-kappa B inhibitor. CKD-712 suppressed MMP-9, but not MMP-2 and other NF-κB-regulated proteins involved in cancer metastasis such as VEGF. CKD-712 induced cell cycle arrest at G2M phase by suppressing cyclin A, cyclin B and C
  • Inquiry Price
6-8 weeks
Size
QTY
CDK6/9-IN-1
CDK6 9-IN-1
T400472414373-55-8
CDK6 9-IN-1 (compound 66) is a potent, orally administered dual inhibitor of CDK6 and CDK9, with IC50 values of 40.5 nM and 39.5 nM, respectively.
  • Inquiry Price
Size
QTY
CDK7/9-IN-1
CDK7 9-IN-1
T403532747919-19-1
CDK7 9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7 9 (CDK7 9), targeting CDK7 with IC50 values of 0.0656 μM without pre-incubation and 0.00574 μM after 3 hours pre-incubation, and displaying inhibitory activity against CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation, making it valuable for cancer research.
  • Inquiry Price
Size
QTY
cdk7-in-16
T627912765676-32-0
CDK7-IN-16 (Compound 9) is a potent inhibitor of CDK 7 (IC50: 1-10 nM). CDK7-IN-16 can be used in research against cancer, particularly cancers with transcriptional abnormalities.
  • Inquiry Price
6-8 weeks
Size
QTY
Ibulocydine
T709881314096-68-8
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7 cyclin H Mat1 and Cdk9 cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibulocydine rapidly blocked phosphorylation of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II, a process mediated by Cdk7 9. Anti-apoptotic gene products such as Mcl-1, survivin, and X-linked IAP (XIAP) are crucial for the survival of many cell types, including HCC. Following the inhibition of RNA polymerase II phosphorylation, ibulocydine caused rapid down-regulation of Mcl-1, survivin, and XIAP, thus inducing apoptosis. Furthermore, ibulocydine effectively ind......
  • Inquiry Price
6-8 weeks
Size
QTY
cdk4/6-in-14
T729512699091-15-9
CDK4 6-IN-14 is a potent, highly selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4 6), with inhibition concentrations (IC50s) of 10 nM and 16 nM, respectively. It shows over 60-fold selectivity for CDK4 6 compared to CDKs 1, 2, 7, and 9, and exhibits significant selectivity against 205 other kinases.
  • Inquiry Price
6-8 weeks
Size
QTY
CDK2-IN-26
T860292821777-43-7
CDK2-IN-26, also known as compound 9, effectively inhibits CDK 2 [1].
  • Inquiry Price
10-14 weeks
Size
QTY